Circulating tumor DNA predicts relapse risk among patients with colorectal cancer

Circulating tumor DNA analysis outperformed an established biomarker in predicting risk for colorectal cancer recurrence after surgery, according to study results presented at Gastrointestinal Cancers Symposium.“Although a high proportion of patients with colon cancer are treated with curative intent, relapse rates remain around 20% to 30%,” Tenna V. Henriksen, a PhD candidate at Aarhus University in Denmark, said during her presentation. “If we are able to identify molecular residual disease, we can enable better recurrence risk assessment. Earlier detection of recurrenceRead More

Share on facebook
Share on twitter
Share on linkedin